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Abstract
Background Accurate and reliable assessment of changes in psoriasis severity is critical in clinical trials of therapies.
Objective To compare Psoriasis Area and Severity Index (PASI), static Physician’s Global Assessment (sPGA), and the
Lattice System Physician’s Global Assessment (LS-PGA) in a trial of systemic treatments for plaque psoriasis vulgaris
and to assess whether they measure change in psoriasis induced by therapy.
Methods Patients were randomized to voclosporin or cyclosporine for 24 weeks (the ‘24-week-treatment’ group,
n = 366), or placebo for 12 weeks followed by voclosporin for 12 weeks (the ‘initial-placebo’ group, n = 89).
Results All scoring systems changed in concert and were sensitive enough to detect reductions in severity during pla-
cebo therapy as well as with active therapy (P < 0.01 for each measurement). At study onset, there were poorer correla-
tions of sPGA with PASI (r = 0.45) and LS-PGA (r = 0.39) than between PASI and LS-PGA (r = 0.68). After therapy, all
correlations were stronger, but sPGA continued to be less well correlated (with PASI, r = 0.85; with LS-PGA, r = 0.79)
than LS-PGA with PASI (r = 0.90). Two- or three-step improvements in LS-PGA showed very good to excellent accuracy
in corresponding to PASI-50 and PASI-75, respectively, and were more accurate than comparable changes in sPGA.
Conclusion PASI, sPGA and LS-PGA are responsive to the varying degrees of improvement in psoriasis induced by
either placebo or active therapy. While the three systems capture similar information, each has different reasons for use
in a clinical trial.
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Introduction
In clinical trials, valid and repeatable measures of disease
severity are essential in assessing efficacy of investigational
treatments for regulatory approval and to compare results
among experimental studies of new therapies.1 Few studies
have examined the validity and reliability of these measures,
challenging our ability to make comparisons among different
clinical trials.1–9
An ideal measurement system to assess disease severity in
psoriasis should be objective, reproducible, easy to use and†Both authors contributed equally to this work
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clinically applicable.1,4,10 Such a validated scoring system, if
unchanging and widely adopted, would help compare studies
and therapies.
Psoriasis Area and Severity Index (PASI, Fig. 1) was invented
for use in a single clinical trial11 and became the most frequently
used measurement of psoriasis severity in clinical trials without
any validation.1,2 Different versions of PASI have been used, and
errors in the formula have surfaced.12 PASI is criticized for being
time-consuming, complicated, lacking sensitivity and difficult to
interpret.13–15 Specific values of PASI (range, 0–72 units) have
been translated into word-based severity terms;16,17 however,
there is no consensus on interpreting a specific value of PASI.
A static Physician’s Global Assessment (sPGA) has many vari-
ations, including 5, 6, or 7-point scoring ranging from ‘clear’ to
‘severe’.14,18 The extent to which body surface area is involved
(iBSA) is not considered in PGA scoring (Fig. 1).
The Lattice System Physician’s Global Assessment (LS-PGA)
was created in response to limitations in other measures.19,20
Unlike most PGAs, it uses iBSA. The iBSA in the LS-PGA is seg-
mented into ranges that, for ease of physician estimation, get lar-
ger as the amount of involvement increases. At low involvement,
the patient’s ‘handprint’ (representing one per cent of the
patient’s surface area) is used21; at higher ranges, intuitive
anchor points are utilized, such as about a quarter of the body
surface involved, about a third to a half and over a half (Fig. 1).
Plaque elevation, erythema and scale severity are specifically
defined. The scores for iBSA and plaque characteristics are
weighted and combined in a computerized lattice algorithm9 to
determine the LS-PGA overall severity of psoriasis. The LS-PGA
formula of weighting the clinical components of psoriasis has
been validated in this clinical trial (see Ref. 22). The LS-PGA has
one current version and its use is controlled to prevent changes
PASI
To obtain PASI in this clinical trial, investigators separately rated 4 regions of the body (head [h], trunk [t],
and upper [u] and lower [l] extremities, not otherwise explained) for erythema (E), infiltration (I),
desquamation (D), and body surface area involved with psoriasis (A). 
Degree of severity in each body region Value given
None 0
Slight 1
Moderate 2
Marked 3
Very marked 4
Surface area involved for each body region Value given
No involvement 0
<10% 1
10-29% 2
30-49% 3
50-69% 4
70-89% 5
90-100% 6
The head, upper extremities, trunk, and lower extremities are assigned 10, 20, 30, and 40 percent, respectively, of 
the total body surface area.  The final PASI calculation is the sum of:
0.1(Eh + Ih + Dh)Ah + 0.2(Eu + Iu + Du)Au + 0.3(Et + It + Dt)At + 0.4(El + Il + Dl)Al. 
The PASI ranges from 0 to 72 unlabeled units.
sPGA
To obtain the sPGA chosen for this clinical trial, investigators began with the interim steps of rating psoriasis 
plaque attributes of induration, erythema, and scaling averaged over the patie nt’s entire body as shown.  
The investigator then decided upon the final sPGA based on the numbered choices shown on the next page.
aInduration
(averaged over all lesions)
bErythema
(averaged over all lesions)
cScaling
(averaged over all lesions)
0 No evidence of plaque elevation
No evidence of erythema; 
hyperpigmentation may be 
present
No evidence of scaling
1 Minimal plaque elevation(≈ 0.5 mm) Faint erythema
Minimal, occasional fine 
scale over less than 5% of 
the lesions
2 Mild plaque elevation(≈ 1 mm) Light red coloration
Mild, fine scale 
predominates
3 Moderate plaque elevation(≈ 1.5 mm) Moderate red coloration
Moderate, coarse scale 
predominates
4 Marked plaque elevation(≈ 2 mm) Bright red coloration
Marked, thick, non-
tenacious scale 
predominates
5 Severe plaque elevation(≈ 2.5 mm or more) Dusky to deep red coloration
Severe, very thick tenacious 
scale predominates
Figure 1 Methods of evaluation of
psoriasis severity. The choices made by the
investigator, as would appear on a Case
Report Form for each evaluation system for
each patient in an investigational trial, are
shown for Psoriasis Area and Severity Index
(PASI), static Physician’s Global
Assessment (sPGA), and the Lattice System
Physician’s Global Assessment (LS-PGA).
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across different studies and their sponsors, thus allowing com-
parisons among clinical trials.
Although the LS-PGA was first described and tested for con-
sistency in 20049, whether it reflects patients’ responses to ther-
apy was questioned.23,24 We hypothesized that the LS-PGA
would demonstrate change during treatment of psoriasis in a
manner similar to PASI and sPGA. Proof of the sensitivity of the
LS-PGA to change during therapy required the cooperation of a
sponsor of a large clinical trial of an effective therapy. These
data, now available for the first time, show that the LS-PGA
demonstrates change in psoriasis severity during a clinical trial
in concert with changes shown by PASI and sPGA. Another
report22 further assesses validity of all three psoriasis evaluation
systems.
Patients, materials and methods
Study design
Data came from a phase III, randomized, multicenter, double-
blind, placebo-controlled study performed in Canada, Germany
and Poland that evaluated the efficacy of voclosporin and cyclo-
sporine in the treatment of psoriasis. Men and women age ≥18
with chronic plaque psoriasis for at least 6 months and iBSA
≥10% were randomized 3 : 1 : 1 to divided-dose voclosporin
Note: When required for comparison purposes, we converted the sPGA numerical range of 0 to 5 to clear = 0,
almost-clear = 1, mild = 2, moderate = 3, marked = 4, and severe = 5. 
LS-PGA
The investigator selects one score in each row that best matches the patient overall, as instructed.
1. INDICATE PERCENT BODY SURFACE INVOLVED (do not include areas with only post-inflammatory 
pigmentation).  The patient's handprint (palm with fingers and thumb held together) approximate a body 
surface area of 1%.
0% 1-3% 4-9% 10-20% 21-29% 30-50% 51-100%
2.  CHECK ONE AND ONLY ONE BOX IN EACH ROW BELOW.  INDICATE AVERAGE QUALITIES ACROSS ALL
INVOLVED AREAS.
Plaque
Quality
NONE MILD MODERATE MARKED
ELEVATION No elevation 
above normal 
skin
(Ignore scale in 
determining 
plaque 
elevation)
Slight elevation 
above surrounding 
normal skin; the 
edges are typically 
barely palpable 
and not seen
(Ignore scale in 
determining 
plaque elevation)
Visually 
apparent elevation 
in plaque edges; 
readily palpated 
edges with 
rounded or sloped 
edges
(Ignore scale in 
determining 
plaque elevation)
Visually obvious 
elevation in plaque 
edges; easily palpated 
with sharp edges that 
provide a discernible 
bump when sliding the 
finger from normal skin 
to the plaque
(Ignore scale in 
determining plaque 
elevation)
ERYTHEMA Normal skin 
color or post-
inflammatory 
color change; 
no erythema
Pink color, 
including “residual 
hyperemia” (“end 
of therapy 
hyperemia”)
Light to 
medium red color
Bright, full, or deep 
red color
SCALE No scales Fine scales 
looking like dust
Individual 
scales discernible 
with yellow to 
silver color
Coarse, thick scales, 
yellow to silver in color; 
plaque has rough 
surface; gives 
impression that scales 
could be lifted with 
fingernail
The selected ratings are used in an algorithm (Langley and Ellis, 2004) to obtain the overall LS-PGA severity score of 
clear, almost-clear, mild, mild to moderate, moderate, moderate to severe, severe, or very severe.  As needed for 
purposes of analysis, we converted the LS-PGA ratings to numeric scores of 0 to 7, respectively.  (LS-PGA Research 
Version 6.0, © and U.S. Pat. 7,955,260, DATAcquire, Inc. [info@datacquire.com].  All rights reserved.  May not be 
reproduced in whole or part without permission; used here with permission.)
Static Physician’s Global Assessment Score (averaged over all lesions):
0 = clear, except for residual discoloration
1 = almost-clear, lesions have individual scores for indurationa erythemab and scalingc (IES) of at least 1
2 = Lesions have individual scores for IES of at least 2
3 = Lesions have individual scores for IES of at least 3
4 = Lesions have individual scores for IES of at least 4
5 = Lesions have individual scores for IES of at least 5
Figure 1 (Continued )
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0.8 mg/kg/day, or cyclosporine 3.0 mg/kg/day, or placebo
respectively. Patients in the voclosporin and cyclosporine arms
were treated for 24 weeks; for purposes of this analysis, these
patients were combined into a ‘24-week-treatment’ group. Those
in the ‘initial-placebo’ group received 12 weeks of placebo; by
protocol, all then received 12 weeks of voclosporin. Patients
with complete data were analysed.
This study (ClinicalTrials.gov NCT00408187) was approved
by regulatory agencies in each country and by an Ethics Com-
mittee at each site. Study investigators adhered to the Guideline
for Good Clinical Practice, which is based on the Declaration of
Helsinki.25
Scoring of psoriasis
Severity was determined at weeks 0, 12 and 24 using PASI, sPGA
and the LS-PGA (DATAcquire, Inc., Ann Arbor, MI, USA, ver-
sion 6.0). Whenever possible, the same investigator at each site
evaluated and scored the patients’ severity of psoriasis through
the trial using all three measurement systems. For sPGA, an
overall score of 0 was a priori defined as ‘clear’ and 1 as ‘almost-
clear’; we labelled the final sPGA scores of 2, 3, 4 and 5 (Fig. 1)
as ‘mild’, ‘moderate’, ‘marked’ and ‘severe’ respectively. We
assigned LS-PGA scores of 0 ‘clear’ through 7 ‘very severe’.
Statistical analysis
A post hoc analysis of the data that is being used in this study
found powers in our various statistical tests above 80% to detect
differences among the methods for measuring psoriasis. To
compare demographical values, we used independent t-tests for
continuous variables and Chi-square or Fisher’s exact test for
categorical variables. Paired t-tests were used to compare mean
psoriasis severity over time by treatment assignment and assess-
ment method, and independent t-tests were used to compare
results between the two treatment assignments. For sPGA and
LS-PGA, we calculated the prevalence ratio of subjects at better
than mild and almost clear at weeks 12 and 24. We calculated
pairwise Spearman’s rank-correlation coefficients for all scoring
systems at all three timepoints.
At weeks 12 and 24, patients who were ‘responders’ by PASI-
50 were compared to ‘responders’ by a two-category reduction
in sPGA or LS-PGA using Chi-square test. Similarly, Receiver
Operating Characteristic (ROC) analysis and 95% confidence
intervals (CIs) were used to compare accuracy of the 2-step and
3-step changes in sPGA and LS-PGA at weeks 12 and 24 using
PASI-50 and PASI-75 respectively as reference standards. ROC
areas under the curve (AUCs) range from 0.5–1.0; we use the
ROC assessment of accuracy of 0.90–1.00 to be excellent;
0.80–0.89, very good; 0.70–0.79, good, 0.60–0.69, fair and
0.50–0.59, poor. We chose 2-step changes in LS-PGA and sPGA
during treatment as our minimal clinically important difference
(MCID) because 1-step changes in severity can occur with little
real change in psoriasis when patient severity is near the border
between any two scores at pretherapy. For PASI, PASI-50 is
regarded as the MCID for a useful therapy. Analyses used SAS
version 9.2.1 (SAS Institute, Cary, NC, USA) and IBM SPSS Sta-
tistics for Windows version 22.0 (International Business
Machines Corporation, Armonk, NY, USA).
Results
Demographics
There were 455 patients who had complete data; 366 patients
were assigned to the 24-week-treatment group and 89 patients
were assigned to the initial-placebo group. Both groups had sim-
ilar initial characteristics (Table 1).
Disease severity
All scoring measures were sensitive enough to detect the effect
caused by placebo therapy along with participating in a clinical
trial; as shown in Table 2, the initial-placebo group improved by
each scoring system after 12 weeks (P < 0.01 for each). All
measures at 12 weeks showed that the 24-week-treatment group
also improved from pretherapy (P < 0.01 for each) and that the
24-week-treatment group showed greater improvement than the
initial-placebo group (Table 2). At week 24, after the initial-
placebo group had received active treatment for 12 weeks, all
severity scores showed further improvement and indicated no
statistical difference in severity between the two assignment
groups (Table 2).
At week 12, both sPGA and LS-PGA indicated that the
24-week-treatment group had a larger proportion of subjects
who achieved a psoriasis score of mild or better (i.e. mild,
almost-clear, or clear) and almost-clear or better (i.e. almost-
clear or clear) compared to the initial-placebo group
(P < 0.0001 for each, Table 3). At week 24, the LS-PGA indi-
cated that the initial-placebo group had nearly caught up to the
24-week-treatment group and that the initial-placebo group and
24-week-treatment group were no longer statistically different
(Table 2). However, the sPGA and PASI suggested that the ini-
tial-placebo group had surpassed the 24-week-treatment group
overall (Table 2) and in achieving scores of mild or better
(P < 0.05 for sPGA, Table 3); the reason for this is unknown.
Correlation of scoring systems
In comparing the relationships of the three measures of psoriasis
severity to each other, PASI and LS-PGA scores were the most
highly correlated in both the 24-week-treatment group and the
initial-placebo group at all timepoints (Table 4). sPGA had
poorer correlations with PASI and LS-PGA, especially at pre-
therapy.
Change from pretherapy
Without regard to assignment to 24-week-treatment or initial-
placebo, 299 subjects could be called responders at week 12 by
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achieving PASI-50. A 2-step improvement in LS-PGA was more
likely to detect these PASI-50 responders than was a 2-step
improvement in sPGA (256 [86%] vs. 203 [68%], respectively,
P < 0.0001). This pattern persisted at week 24.
Using ROC analysis, a 2-step improvement at 12 weeks in
LS-PGA was more likely to detect PASI-50 responders than
was a 2-step improvement in sPGA (AUC 0.88 [95% CI, 0.84–
0.91] vs. AUC 0.81 [95% CI, 0.77–0.85] respectively). After
24 weeks, the results were similar but closer to each other
(AUC 0.82 [95% CI, 0.76–0.87] vs. AUC 0.79 [95% CI, 0.74–
0.84] respectively). Similar results were found when 3-step
changes were compared to PASI-75; at 12 weeks, the AUCs
were 0.86 (0.82–0.91) for LS-PGA vs. 0.71 (0.66–0.76) for
sPGA; at 24 weeks, 0.80 (0.76–0.85) for LS-PGA vs. 0.70 (0.65–
0.75) for sPGA.
Discussion
This is the first report directly comparing PASI, sPGA and LS-
PGA in a clinical trial. Previously, all three scoring systems
correlated highly with one another when dermatologists evalu-
ated patients with psoriasis on a single day.9,14,26,27 With this
analysis, we have now proved that PASI, sPGA and LS-PGA
demonstrate change with active therapy, distinguish active from
placebo therapy and track in parallel and correlate well overall
(Tables 1–4) over the course of a typical psoriasis clinical trial.
All three systems detected a wide range of change, including the
modest change that occurs with placebo28,29 and the greater
effect of oral calcineurin therapy (Table 2). As expected, most
patients in this trial who achieved final sPGA and LS-PGA scores
of almost-clear or clear also achieved PASI-75 and PASI-90 (data
not shown).
Table 1 Demographics and pretherapy psoriasis severity of study participants, stratified by treatment assignment. There were no signifi-
cant differences in pretherapy characteristics between the 24-week-treatment group (patients who received active therapy throughout
the study) and initial-placebo group (patients who received placebo for 12 weeks and active therapy for 12 weeks). Psoriasis Area and
Severity Index has a range of 0 to 72
Total (n = 455) 24-Week-Treatment (n = 366) Initial-Placebo (n = 89)
Sex, n (%)
Female 142 (31) 116 (32) 26 (29)
Male 313 (69) 250 (68) 63 (71)
Race/ethnicity, n (%)
Caucasian 437 (96) 353 (97) 84 (94)
Asian 13 (3) 9 (3) 4 (5)
Black 1 (<1) 0 (0) 1 (1)
Hispanic 1 (<1) 1 (<1) 0 (0)
Native American 1 (<1) 1 (<1) 0 (0)
Other 2 (<1) 2 (<1) 0 (0)
Age, mean (SD)
43 (13) 43 (13) 45 (13)
Psoriasis Area and Severity Index, mean (SD)
18.4 (7.0) 18.5 (7.1) 17.9 (6.4)
Static Physician’s Global Assessment, n (%)
0 0 (0) 0 (0) 0 (0)
1 0 (0) 0 (0) 0 (0)
2 3 (<1) 3 (<1) 0 (0)
3 260 (57) 205 (56) 55 (62)
4 174 (38) 140 (38) 34 (38)
5 18 (4) 18 (5) 0 (0)
Lattice System Physician’s Global Assessment, n (%)
Clear 0 (0) 0 (0) 0 (0)
Almost-clear 0 (0) 0 (0) 0 (0)
Mild 0 (0) 0 (0) 0 (0)
Mild-to-moderate 0 (0) 0 (0) 0 (0)
Moderate 13 (3) 10 (3) 3 (3)
Moderate-to-severe 125 (28) 99 (27) 26 (29)
Severe 199 (44) 164 (45) 35 (39)
Very severe 118 (26) 93 (25) 25 (28)
SD, standard deviation.
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The correlation between PASI and LS-PGA was better at all
timepoints than was sPGA with either of the other assessment
systems. While perfect correlations were not expected (which
would indicate that all three systems yield identical results), a
high correlation was expected because the systems use similar
aspects of psoriasis assessments. Because iBSA is not a specified
component of sPGA (but is used in the algorithms to compute
PASI and the LS-PGA), this may account for the poorer correla-
tion of sPGA with the other measures.
Not using iBSA removes an important characteristic that
often influences how severe psoriasis is perceived to be. Because
iBSA in theory is not considered in disease severity in sPGA, a
patient with one small plaque should be scored the same as a
patient with numerous similar plaques. However, in practice,
physicians likely consider iBSA when determining sPGA. Indeed,
iBSA was statistically more closely associated with sPGA score
than was plaque elevation, erythema, or scale.9 As a result of
physicians’ apparent innate use of iBSA in determining sPGA
scores despite being instructed not to do so, exclusion of iBSA in
sPGA may increase variability across investigator sites and
among clinical trials.
This study used a version of sPGA that defined many psoriasis
plaque qualities and included instructions on combining the
plaque qualities into the final score (Fig. 1). In many versions of
sPGA, psoriasis is defined simply as mild, moderate, or severe;
some are even more vague.9 Because sPGA definitions differ
among studies, and because investigators participating in more
than one study may have difficulty in adjusting their thresholds
of severity for each, one must be cautious in directly comparing
sPGA across clinical trials.
Standardized evaluation systems that are accurate, consistent
and clinically meaningful and that allow comparisons among
studies and across therapies are desired.4,7,30 However, different
Table 3 Prevalence of subjects at or below various thresholds of sPGA and LS-PGA at week 12 and 24. The initial-placebo group
crossed over to active treatment after week 12. The P values were obtained from testing the null hypothesis that the proportion of sub-
jects who achieved the various outcomes between the two assignment groups is equal
Threshold* 24-Week-Treatment
(n = 366) n (%)
Initial-Placebo
(n = 89) n (%)
Prevalence ratio estimate
(95% CI) of 24-Week-Treatment vs.
Initial-Placebo†
P
Week 12
sPGA≤almost-clear 150 (41) 7 (8) 5.2 (2.5, 10.7) <0.0001
sPGA≤mild 264 (72) 21 (24) 3.1 (2.1, 4.5) <0.0001
LS-PGA≤almost-clear 100 (27) 3 (3) 8.1 (2.6, 25.0) <0.0001
LS-PGA≤mild 176 (48) 11 (12) 3.9 (2.2, 6.8) <0.0001
Week 24
sPGA≤almost-clear 161 (44) 41 (46) 1.0 (0.7, 1.2) 0.72
sPGA≤mild 268 (73) 74 (83) 0.9 (0.8, 1.0)‡ 0.05‡
LS-PGA≤almost-clear 113 (31) 22 (25) 1.2 (0.8, 1.9) 0.25
LS-PGA≤mild 208 (57) 49 (55) 1.0 (0.8, 1.3) 0.76
≤almost-clear, almost-clear or clear; ≤mild, mild, almost-clear, or clear; CI, confidence interval; LS-PGA, Lattice System Physician’s Global Assessment;
sPGA, Static Physician’s Global Assessment.
*An sPGA score of 2 was assigned the term ‘mild’.
†A prevalence ratio 95% CI that includes 1 indicates no statistical difference between the two assignment groups.
‡The upper limit of the CI is <1 and P < 0.05; however, they appear as shown due to rounding. Among the initial-placebo patients, there was a higher
percentage who achieved sPGA≤mild after receiving 12 weeks of active therapy compared to the patients in the 24-week-treatment group. This may
have occurred due to chance (in view of the CI approaching 1) or due to our arbitrary assignment of the rubric ‘mild’ to level 2 of the sPGA. This occur-
rence was not seen with use of the LS-PGA.
Table 2 Mean psoriasis severity by treatment assignment and
assessment method. The initial-placebo group crossed over to
active therapy at week 12. The P value was obtained from testing
the null hypothesis that the mean psoriasis severity is equal
between the 24-week-treatment and initial-placebo groups
Pretherapy Week 12 Week 24
Psoriasis Area and Severity Index
24-Week-Treatment 18.5 6.3* 5.4†
Initial-Placebo 17.9 14.3* 5.1†
P value 0.48 <0.01 0.63
Static Physician’s Global Assessment
24-Week-Treatment 4.0 1.8* 1.7†
Initial-Placebo 3.5 2.9* 1.6†
P value 0.19 <0.01 0.35
Lattice System Physician’s Global Assessment
24-Week-Treatment 5.9 3.2* 2.8†
Initial-Placebo 5.9 5.0* 3.0†
P value 0.94 <0.01 0.38
*P < 0.01 comparing mean psoriasis severity at week 12 compared to
pretherapy within each assignment group.
†P < 0.01 comparing mean psoriasis severity at week 24 compared to
pretherapy within each assignment group.
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versions of PASI have been used in various clinical trials, and
PASI scoring lacks clear definitions. PASI has significant intra-
rater and interrater variation that is affected by the experience
level of the evaluator9 and can be difficult and time-consuming
to do, especially with limited experience. In PASI, the iBSA must
be determined separately for each segment of the body, a provi-
sion that may induce errors, particularly at small degrees of
involvement when the handprint method21 cannot be used
because the patient’s handprint covers 1% of the entire body,
not 1% of the segment being scored.
Despite its wide use, the numerical PASI score has no intuitive
meaning to patients or physicians7,9,13,14,18,31–33 and lacks clini-
cal relevance for many dermatologists, in part because it is rarely
used in clinical practice, particularly in the USA. Although PASI
is non-linear, treatment success for individual patients in clinical
trials of investigational therapies for psoriasis has been PASI- 50
or PASI-75. This has been problematic, because some patients
with improvements less than these cutoffs have clinically mean-
ingful success or achieve satisfaction with their therapy, while
others still have extensive psoriasis or lack satisfaction after
achieving even PASI-75.18,26,34–36
For a subject to achieve treatment success in a clinical trial,
the U.S. Food and Drug Administration (FDA) expects the
patient’s psoriasis severity to reach clear or almost-clear, a
threshold that is not defined by PASI number or by a specific
reduction of PASI score. The FDA and the European Medicines
Agency (EMA) do not support the use of PASI alone to gauge
psoriasis severity for approval of new therapies in phase III trials
and suggest use of a validated, standardized scoring system that
produces word scores; the EMA guidance specifically mentions
the LS-PGA or an sPGA.37
sPGA scores have clinical context regarding severity and are
typically quick and easy to perform. Unfortunately, multiple
versions of sPGAs exist, most of which lack clear definitions;
furthermore, sPGAs are designed not to take iBSA into account.
A newer measure, the LS-PGA, is a standard method for evalu-
ating psoriasis severity; provides clear definitions of severity of
each component of psoriasis and intuitive estimations of iBSA;
is quick and easy to perform by checking only four boxes
(Fig. 1); yields a clinically relevant score; and has reproducible
results.9,14
To be used with confidence, a new system must be shown to
detect the effect of treatment; in this large clinical trial, the
LS-PGA proved sensitive to changes in disease severity during
therapy in concert with PASI and an sPGA. Furthermore, a
two- or three-category reduction in the LS-PGA was more often
associated with PASI-50 or PASI-75 respectively than was sPGA
at both evaluation timepoints, and the confidence range of accu-
racy for the LS-PGA was very good to excellent. Because two and
three-category reductions in the LS-PGA so consistently reflect
PASI-50 or PASI-75, such changes in LS-PGA may be used to
assess clinically significant improvement in psoriasis.
This research studies the evaluation of psoriasis severity in
clinical trials; it does not fully assess the efficacy of voclosporin
or any other treatment; drug efficacy was used solely to test the
scoring systems. Therefore, the group of patients treated with
calcineurin inhibitors meets all requirements for this research.
The trial sponsor did not identify to us which patients in the
24-week-treatment group received voclosporin and which
received cyclosporine. Even with that identification, to evaluate
psoriasis rating systems we would have performed the exact
same combined group analyses that are presented in this report.
Additional analysis of subgroups receiving the two similarly
active calcineurin inhibitors would only result in smaller num-
bers in each group as compared to the combined group.
Our data indicate that all three severity measures used in this
psoriasis clinical trial, namely the LS-PGA, PASI and sPGA, may
be used to monitor change induced by placebo or active therapy.
In theory, any one of the measurements would do, so how do
designers of clinical trials select the evaluation systems to be
used? PASI is often chosen for use in a new clinical trial to allow
comparison to data from prior trials that reported PASI. How-
ever, in comparing various trials, the severity of patients’ psoria-
sis before therapy may be important when attempting to
compare patients’ percentage changes (e.g. PASI-75) across stud-
ies because a 75 per cent reduction from a large extent of psoria-
sis may be a different result from the same per cent reduction if
starting from a much lesser extent of involvement.
Table 4 Spearman’s rank-correlation coefficients (r) between Psoriasis Area and Severity Index (PASI), Static Physician’s Global Assess-
ment (sPGA) and Lattice System Physician’s Global Assessment (LS-PGA) at pretherapy, week 12 and week 24. The 24-week-treatment
group is the patients who received active therapy throughout the study; the initial-placebo group is the patients who received placebo for
12 weeks followed by active therapy for 12 weeks
PASI and sPGA PASI and LS-PGA LS-PGA and sPGA
24-Week-Treatment
(n = 366)
Initial-Placebo
(n = 89)
24-Week-Treatment
(n = 366)
Initial-Placebo
(n = 89)
24-Week-Treatment
(n = 366)
Initial-Placebo
(n = 89)
Pretherapy 0.45 0.23 0.68 0.63 0.39 0.26
Week 12 0.83 0.75 0.91 0.83 0.76 0.59
Week 24 0.85 0.72 0.90 0.86 0.79 0.58
P < 0.05 for all r values (testing the null hypothesis that r = 0).
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To meet regulatory requirements, a severity measure that pro-
vides a word-based result (e.g. severe, mild, almost-clear, etc.) is
desired. A version of the sPGA typically is chosen, usually with
the concurrence of the FDA or EMA. However, the selected
sPGA may differ from previous studies, may be poorly defined,
and usually does not incorporate extent of psoriasis. Alterna-
tively, the well-defined LS-PGA includes measurement of psoria-
sis extent and may be used to provide a word-based result that
can be compared across studies. However, it is not yet widely
used and awaits greater familiarity. In practice, and as in the trial
reported here, two or more severity systems are commonly
employed to satisfy various interests in the clinical trial.
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